JESUS ZEPEDA: Open Payments
NPI 1891932083 · MONTEBELLO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,193 in 126 payments from 24 companies in 2025. Trend: 2023 $1,509 · 2024 $2,776 · 2025 $3,193
Food & beverage: $3,193
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 18 | $504 |
| Novo Nordisk Inc | 17 | $473 |
| Dexcom, Inc. | 10 | $293 |
| Ascendis Pharma Endocrinology Inc | 7 | $227 |
| Lilly USA, LLC | 7 | $187 |
| Ascensia Diabetes Care Us Inc. | 14 | $184 |
| Averitas Pharma Inc. | 6 | $182 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $144 |
| Novartis Pharmaceuticals Corporation | 4 | $129 |
| BETA BIONICS, INC. | 5 | $123 |
Products named: Wegovy, Dexcom G6 Transmitter, TEPEZZA, Yorvipath, QUTENZA, MOUNJARO, JARDIANCE, Ozempic.
Industry payments across CA — which companies pay providers there.
